A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines

Molecular Pharmaceutics

Volumn 8, Issue 6, 2011, Pages 2252-2261

  Pimienta, Genaro ^a   Herbert, Kristina M ^a   Regan, Lynne ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

chaperone inhibitor Hsp70; JNK1 2; p38; triple negative breast cancer

Indexed keywords

1,6 DIMETHYL 3 PROPYLPYRIMIDO[5,4 E][1,2,4]TRIAZINE 5,7 DIONE; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEIN HOP; PROTEIN INHIBITOR; PU H71; TANESPIMYCIN; TRIAZINE DERIVATIVE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CELL MATURATION; CELL SURVIVAL; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN FOLDING; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; FIBROBLASTS; HOMEODOMAIN PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PYRIMIDINONES; TRIAZINES; TUMOR SUPPRESSOR PROTEINS;

EID: 82955169612     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200346y     Document Type: Article

References (51)

1. Biamonte, M. A. Heat shock protein 90: inhibitors in clinical trials J. Med. Chem. 2010, 53 (1) 3-17
2. Janin, Y. L. ATPase inhibitors of heat-shock protein 90, second season Drug Discovery Today 2010, 15 (9-10) 342-53
3. Pearl, L. H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery Annu. Rev. Biochem. 2006, 75, 271-94 (Pubitemid 44118034)
4. Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery Exp. Biol. Med. (Maywood) 2003, 228 (2) 111-33 (Pubitemid 36187918)
5. Caplan, A. J.; Mandal, A. K.; Theodoraki, M. A. Molecular chaperones and protein kinase quality control Trends Cell Biol. 2007, 17 (2) 87-92 (Pubitemid 46199182)
6. Powers, E. T. Biological and chemical approaches to diseases of proteostasis deficiency Annu. Rev. Biochem. 2009, 78, 959-91
7. Powers, M. V.; Clarke, P. A.; Workman, P. Death by chaperone: HSP90, HSP70 or both? Cell Cycle 2009, 8 (4) 518-26
8. Kundrat, L.; Regan, L. Identification of residues on Hsp70 and Hsp90 ubiquitinated by the cochaperone CHIP J. Mol. Biol. 2010, 395 (3) 587-94
9. Kundrat, L.; Regan, L.;, Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. Biochemistry. 49 (35): p. 7428-38.
10. Stebbins, C. E. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 1997, 89 (2) 239-50 (Pubitemid 27199896)
11. Roe, S. M. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin J. Med. Chem. 1999, 42 (2) 260-6 (Pubitemid 29069861)
12. Solit, D. B. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin. Cancer Res. 2002, 8 (5) 986-93 (Pubitemid 34517631)
13. Ge, J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 J. Med. Chem. 2006, 49 (15) 4606-15 (Pubitemid 44162687)
14. Solit, D. B. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer Clin. Cancer Res. 2007, 13 (6) 1775-82 (Pubitemid 46952945)
15. Solit, D. B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma Clin. Cancer Res. 2008, 14 (24) 8302-7
16. McCollum, A. K. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism Cancer Res. 2006, 66 (22) 10967-75 (Pubitemid 44876996)
17. Maloney, A. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin Cancer Res. 2007, 67 (7) 3239-53 (Pubitemid 46724862)
18. Caldas-Lopes, E. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (20) 8368-73
19. Gaspar, N. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma Mol. Cancer Ther. 2010, 9 (5) 1219-33
20. Yi, F.; Regan, L. A novel class of small molecule inhibitors of Hsp90 ACS Chem. Biol. 2008, 3 (10) 645-54
21. Hartl, F. U.; Hayer-Hartl, M. Converging concepts of protein folding in vitro and in vivo Nat. Struct. Mol. Biol. 2009, 16 (6) 574-81
22. Eccles, S. A. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res. 2008, 68 (8) 2850-60 (Pubitemid 351556284)
23. Lu, Z.; Hunter, T. Degradation of activated protein kinases by ubiquitination Annu. Rev. Biochem. 2009, 78, 435-75
24. Lopez-Otin, C.; Hunter, T. The regulatory crosstalk between kinases and proteases in cancer Nat. Rev. Cancer 2010, 10 (4) 278-92
25. Ota, A. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte Circ. Res. 2010, 106 (8) 1404-12
26. Nieto-Miguel, T. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy Oncogene 2008, 27 (12) 1779-87 (Pubitemid 351380270)
27. Gutierrez, G. J. Interplay between Cdh1 and JNK activity during the cell cycle Nat. Cell Biol. 2010, 12 (7) 686-95
28. Yi, F. An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction J. Biomol. Screening 2009, 14 (3) 273-81
29. Neve, R. M. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 2006, 10 (6) 515-27 (Pubitemid 44854747)
30. Munster, P. N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells Cancer Res. 2001, 61 (7) 2945-52 (Pubitemid 32691939)
31. Pickl, M.; Ries, C. H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab Oncogene 2009, 28 (3) 461-8
32. Weigelt, B.; Lo, A. T.; Park, C. C.; Gray, J. W.; Bissell, M. J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment Breast Cancer Res. Treat. 2010, 122 (1) 35-43
33. Ivascu, A.; Kubbies, M. Diversity of cell-mediated adhesions in breast cancer spheroids Int. J. Oncol. 2007, 31 (6) 1403-13
34. Korkaya, H. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 2008, 27 (47) 6120-30
35. Wolf, K. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis J. Cell Biol. 2003, 160 (2) 267-77 (Pubitemid 36254960)
36. Xu, W. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 J. Biol. Chem. 2001, 276 (5) 3702-8
37. Theodoraki, M. A. Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context Exp. Cell Res. 2007, 313 (18) 3851-8 (Pubitemid 47561893)
38. Smith, J. R. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors Oncogene 2009, 28 (2) 157-69
39. Zhang, T. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells Mol. Cancer Ther. 2008, 7 (1) 162-70
40. Ota, A. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte Circ. Res. 2010, 106 (8) 1404-12
41. Garrido, C. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties Cell Cycle 2006, 5 (22) 2592-601 (Pubitemid 44785803)
42. Voellmy, R. On mechanisms that control heat shock transcription factor activity in metazoan cells Cell Stress Chaperones 2004, 9 (2) 122-33 (Pubitemid 39013809)
43. Johnston, P. A. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents Assay Drug Dev. Technol. 2008, 6 (4) 505-18
44. 2 in HTS buffers containing strong reducing reagents-real hits or promiscuous artifacts? Curr. Opin. Chem. Biol. 2011, 15 (1) 174-82
45. Soares, K. M. Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments Assay Drug Dev. Technol. 2010, 8 (2) 152-74
46. Stockmans, G. Triple-negative breast cancer Curr. Opin. Oncol. 2008, 20 (6) 614-20
47. Carey, L. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 2010, 7 (12) 683-92
48. Huang, C. JNK phosphorylates paxillin and regulates cell migration Nature 2003, 424 (6945) 219-23 (Pubitemid 36858692)
49. Shin, I. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells J. Biol. Chem. 2005, 280 (15) 14675-83 (Pubitemid 40562814)
50. Kaoud, T. S. Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell Migration ACS Chem. Biol. 2011, 6 (6) 658-66
51. Mingo-Sion, A. M. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells Oncogene 2004, 23 (2) 596-604 (Pubitemid 38175015)